Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVAC NYSE:RCUS NASDAQ:STOK NASDAQ:TLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$5.34-0.9%$5.42$2.37▼$5.72$1.20B2.53432,650 shs1.22 million shsRCUSArcus Biosciences$11.50$10.02$6.50▼$18.98$1.22B0.83721,220 shs711,202 shsSTOKStoke Therapeutics$23.46-1.8%$16.05$5.35▼$24.60$1.31B1.14957,451 shs1.03 million shsTLMDSOC Telemed$3.00$2.98$0.55▼$8.00$302.52M-1.441.28 million shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac-0.93%-0.93%-2.91%-4.13%+76.24%RCUSArcus Biosciences-0.04%-5.89%+14.31%+24.32%-32.27%STOKStoke Therapeutics-1.76%+13.44%+38.73%+103.47%+59.16%TLMDSOC Telemed0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$5.34-0.9%$5.42$2.37▼$5.72$1.20B2.53432,650 shs1.22 million shsRCUSArcus Biosciences$11.50$10.02$6.50▼$18.98$1.22B0.83721,220 shs711,202 shsSTOKStoke Therapeutics$23.46-1.8%$16.05$5.35▼$24.60$1.31B1.14957,451 shs1.03 million shsTLMDSOC Telemed$3.00$2.98$0.55▼$8.00$302.52M-1.441.28 million shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac-0.93%-0.93%-2.91%-4.13%+76.24%RCUSArcus Biosciences-0.04%-5.89%+14.31%+24.32%-32.27%STOKStoke Therapeutics-1.76%+13.44%+38.73%+103.47%+59.16%TLMDSOC Telemed0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac 2.20Hold$6.8327.97% UpsideRCUSArcus Biosciences 2.75Moderate Buy$21.1483.85% UpsideSTOKStoke Therapeutics 3.22Buy$25.579.00% UpsideTLMDSOC Telemed 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TLMD, STOK, CVAC, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025STOKStoke TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$28.008/13/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/13/2025STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $22.008/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$26.00 ➝ $25.007/18/2025STOKStoke TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.007/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.006/26/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.506/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$510.51M2.35$0.87 per share6.17$3.36 per share1.59RCUSArcus Biosciences$262M4.67N/AN/A$5.30 per share2.17STOKStoke Therapeutics$199.89M6.43N/AN/A$4.32 per share5.43TLMDSOC Telemed$94.44M3.20N/AN/A$1.66 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac$175.50M$0.965.56N/AN/A38.21%29.57%25.41%11/11/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8527.60N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)TLMDSOC Telemed-$50.54M-$0.57N/A∞N/A-53.52%-34.32%-20.96%N/ALatest TLMD, STOK, CVAC, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025CVACCureVac-$0.15-$0.30-$0.15-$0.30$4.27 million$1.41 million8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ATLMDSOC TelemedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.056.176.16RCUSArcus Biosciences0.184.504.50STOKStoke TherapeuticsN/A6.986.98TLMDSOC Telemed0.523.323.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%RCUSArcus Biosciences92.89%STOKStoke TherapeuticsN/ATLMDSOC TelemedN/AInsider OwnershipCompanyInsider OwnershipCVACCureVac2.15%RCUSArcus Biosciences9.60%STOKStoke Therapeutics9.50%TLMDSOC Telemed6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac880224.34 million219.52 millionOptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableTLMDSOC Telemed226100.84 million93.88 millionOptionableTLMD, STOK, CVAC, and RCUS HeadlinesRecent News About These CompaniesThe Woman’s World Expert-Reviewed Glossary of GLP-1, Semaglutide and TelehealthNovember 14, 2024 | yahoo.comTrial reveals success of telemedicine-supported, village doctor–led approach to managing atrial fibrillationSeptember 2, 2024 | msn.comExplore the Innovations of Dr. Todd H. Lanman: An Influence in Spinal NeurosurgeryAugust 27, 2024 | usatoday.comComparative Studies in Society and HistoryAugust 24, 2024 | cambridge.orgCFrom science fiction to telemedicine: the surprising 150-year history of long-range medical treatmentAugust 9, 2024 | theconversation.comTTaipei Medical University Hospital successfully advances telemedicine, leveraging technology to provide comprehensive healthcareAugust 9, 2024 | digitimes.comDNavigating telemedicine and online doctors in Louisiana for more 'consumer-centric' careAugust 4, 2024 | nola.comNTelemedicine usage can have unexpected impact on rural communities' access to local careAugust 2, 2024 | msn.comCalifornia's Telemedicine Restrictions Are Forcing Rare Disease Patients To Travel Out of State for CareMay 23, 2024 | reason.comROne reader’s view | Cowlitz County Humane Society director urges expanding telemedicine for petsMay 10, 2024 | tdn.comTSociety ManMay 2, 2024 | bloodhorse.comBAccess to remote learning, telemedicine during extreme weather events ending for millionsMay 2, 2024 | nypost.comNTelemedicine Reduces Rehospitalization, Revascularization in Post-PCI ACS PatientsApril 7, 2024 | medscape.comMTelehealth Improves Hepatitis C Treatment in Patients With Opioid Use DisorderApril 4, 2024 | medpagetoday.comMUT Southwestern, Dallas telemedicine company partner on study to improve heart health in rural communitiesApril 4, 2024 | bizjournals.comMobile pet telehealth app expands offeringsApril 1, 2024 | dvm360.comDBill allowing telemedicine for pets awaits Gov. DeSantis' signatureMarch 11, 2024 | fox13news.comFDallas Trio To Bring ‘Specialists to Patients’ With Rural Cardiac Telemedicine PilotMarch 7, 2024 | dallasinnovates.comDJournal of the Royal Asiatic SocietyFebruary 29, 2024 | cambridge.orgC(LEAD) Gov't to fully allow telemedicine services in case of doctors' collective actionFebruary 19, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLMD, STOK, CVAC, and RCUS Company DescriptionsCureVac NASDAQ:CVAC$5.34 -0.05 (-0.93%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.32 -0.02 (-0.30%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Arcus Biosciences NYSE:RCUS$11.50 0.00 (0.00%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$11.40 -0.10 (-0.83%) As of 09/12/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Stoke Therapeutics NASDAQ:STOK$23.46 -0.42 (-1.76%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.70 +0.24 (+1.02%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.SOC Telemed NASDAQ:TLMDSOC Telemed, Inc. provides acute care telemedicine services and technology to hospitals, health systems, physician groups, and government organizations in the United States. The company's Telemed IQ, a cloud-based software platform provides telemedicine solutions. Its telemedicine solutions include teleNeurology, telePulmonology, telePsychiatry, telecardiology, teleCritical Care (ICU), and other specialties. The company was founded in 2004 and is based in Herndon, Virginia. As of April 6, 2022, SOC Telemed, Inc. was taken private. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
